Supplementary appendix Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 24 mg for weight management: a randomised, controlled, phase 1b trial ScienceDirect Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial ScienceDirect New trial data on CagriSema 23% weight loss at 84 weeks in the RE DEFINE 4 trial. CagriSema pairs semaglutide with cagrilintide, an amylin analogue. Amylin is a pancreatic hormone that slows